For the quarter ending 2025-12-31, BTCY made $3,987,819 in revenue. -$1,162,614 in net income. Net profit margin of -29.15%.
| Income Statement | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2024-12-31 |
|---|---|---|---|---|
| Revenue | 3,987,819 | 3,885,795 | 3,873,993 | 3,619,108 |
| Cost of revenue | 736,343 | 704,297 | 757,193 | 855,140 |
| Gross profit | 3,251,476 | 3,181,498 | 3,116,800 | 2,763,968 |
| Selling, general and administrative expenses | 2,186,994 | 2,304,881 | 2,138,692 | 2,381,734 |
| Research and development expenses | 623,567 | 602,798 | 696,163 | 551,216 |
| Total operating expenses | 2,810,561 | 2,907,679 | 2,834,855 | 2,932,950 |
| (loss) profit from operations | 440,915 | 273,819 | 281,945 | -168,982 |
| Other income/(expense) | -39,247 | 106,599 | 66,671 | 65,512 |
| Interest expense | 810,339 | 860,419 | 850,254 | - |
| Gain/(loss) upon convertible promissory notes conversion and redemption note 5 | 11,409 | - | 8,433 | -17,357 |
| Accretion and amortization expenses | -185,470 | -202,141 | -153,572 | -291,128 |
| Interest expense | - | - | - | 849,538 |
| Change in fair value of derivative liabilities note 8 | -134,335 | -8,771 | -25,200 | 32,339 |
| Net loss before income taxes | -717,067 | -690,913 | -671,977 | -1,229,154 |
| Income taxes note 3 | - | - | 0 | - |
| Net loss before dividends | -717,067 | -690,913 | -671,977 | -1,229,154 |
| Preferred stock dividends | 431,000 | 81,410 | 82,316 | 89,392 |
| Deemed dividends note 9 | - | - | 0 | - |
| Net loss attributable to common stockholders | -1,148,067 | -772,323 | -754,293 | -1,318,546 |
| Translation adjustment | -14,547 | 9,286 | -36,169 | 76,680 |
| Comprehensive loss | -1,162,614 | -763,037 | -790,462 | -1,241,866 |
| Basic EPS | -0.042 | -0.029 | -0.029 | -0.054 |
| Diluted EPS | -0.042 | -0.029 | -0.029 | -0.054 |
| Basic Average Shares | 27,590,766 | 26,767,370 | 26,284,734 | 24,232,369 |
| Diluted Average Shares | 27,590,766 | 26,767,370 | 26,284,734 | 24,232,369 |
BIOTRICITY INC. (BTCY)
BIOTRICITY INC. (BTCY)